A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States

A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States

Expanding serotype coverage of pneumococcal conjugate vaccines (PCVs) to target prevailing disease-causing serotypes could further reduce disease burden. To address this need, 2 different PCVs have been investigated: a 20-valent PCV (PCV20; includes the 13 serotypes in the 13-valent PCV [PCV13] plus...

Full description

Bibliographic Details
Main Authors: David Fitz-Patrick, Mariano Young Jr, Daniel A. Scott, Ingrid L. Scully, Gary Baugher, Yahong Peng, Kathrin U. Jansen, William Gruber, Wendy Watson
Format: Article
Language:English
Published: Taylor & Francis Group 2021-07-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
streptococcus pneumoniae
clinical trial
pneumococcal conjugate vaccine
immunogenicity
safety
pcv20
cpcv7
Online Access:http://dx.doi.org/10.1080/21645515.2020.1863177

Internet

http://dx.doi.org/10.1080/21645515.2020.1863177

Similar Items